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Introduction
The pathogenic mechanisms responsible for the CD4 + T cell depletion in acquired immunodeficiency syndrome (AIDS) are not completely understood, as evidence supports both direct and indirect mechanisms for loss of this key lymphocyte population.
During primary infection, a high frequency of CD4 + T cells are infected by HIV-1, and lysis and/or immunological clearance of these infected cells accounts for substantial early depletion of CD4 + T cells, particularly when mucosal tissues are sampled 1, 2 . Thus, direct killing of infected cells appears to contribute to the loss of CD4 + T cells in primary HIV-1 infection. However, other observations suggest that immune mechanisms contribute to HIV-1-induced death of CD4 + T cells 3, 4 . Apoptosis of uninfected CD4 + T cells was suggested as a mechanism 5 particularly during the chronic stage of infection and during progression to AIDS. Because the loss of circulating CD4 + T cells during HIV-1 disease progression is greater than that of CD8 + T cells, we were interested in mechanisms of T cell death that might preferentially affect CD4 + T cells.
The Fas/FasL apoptotic pathway has been studied extensively and was suggested as a mechanism that contributes to apoptosis of CD4 + T cells in AIDS 6 . Several models showed that CD4 cross-linking and Fas ligation resulted in apoptosis of CD4 + and CD8 + T cells [7] [8] [9] . However, death mechanisms other than Fas/FasL may contribute to apoptosis of CD4 + T cells during AIDS 10, 11 . Because the primary immunologic consequence of HIV-1 infection is CD4 + T cell depletion, our objective was to develop a model that selectively affects CD4 + T cells upon exposure to HIV-1.
TNF-Related Apoptosis-Inducing Ligand (TRAIL), a TNF superfamily member 12 , induces apoptosis of virus-infected 13 and tumor cells 14 . TRAIL has two death Several studies suggested a role of TRAIL in apoptosis of CD4 + T cells in HIV infection. For example, CD4 + and CD8 + T cells from HIV-1-infected patients were more susceptible to TRAIL-induced apoptosis in vitro than T cells from healthy donors [18] [19] [20] .
TRAIL induced selective apoptosis of uninfected CD4 + T cells in an HIV-1-infected hu-PBL-NOD-SCID mice 21 . TRAIL produced by monocytes exposed to the HIV- 
Patients, materials and methods

HIV-1-infected patients
Blood was collected from 22 HIV-1-infected patients and 16 uninfected donors. In addition, eight patients from a different cohort involved in a longitudinal study of HAART were followed for 40 weeks. These eight patients received the combination of Viread (tenofivir), Zerit (stavudine), and Kaletra (lopinavir/ritonavir) or the combination of Trizivir (zidovudine/lamivudine/abacavir), Combivir (zidovudine/lamivudine), and Sustiva (efavirenz). Plasma HIV-1 RNA was measured by a quantitative RT-PCR assay; all data are expressed as copies/ml (Amplicor Monitor; Roche Diagnostic Systems, Branchburg, NY, USA; detection limit 50 copies/ml). All patients were studied under IRB-approved protocols and consent forms from the National Cancer Institute, and Wilford Medical Center.
Isolation and culture of T cells and pDCs
All in vitro experiments were performed using PBMC isolated by Ficoll density centrifugation from blood obtained from HIV- hours, control and HIV-1MN plus anti-DR5-treated cells were stained using an antimouse-PE antibody (BD Bioscience), and cells cultured with HIV-1MN plus isotype were stained using the anti-DR5 antibody, followed by anti-mouse-PE antibody. This technique allowed us to block and then detect cells that are not undergoing apoptosis (Annexin V negative) but expressing DR5 (DR5 + ). Polyclonal anti-IFN-/ antibodies were used at 2000 and 500 neutralizing U/mL, respectively (BioSource International, Camarillo, CA). Mouse IgG isotype control antibody (BD Bioscience) was used at 5µg/mL. Apoptosis was assessed by the Annexin V method.
We also tested whether HIV-1-induced apoptosis and DR5 mRNA expression would be inhibited by: 1) soluble CD4-IgG (sCD4-IgG), and 2) AMD-3100 and RANTES. CD4 + cells were cultured 24 hours with AT-2 HIV-1 MN/Ada in the presence of sCD4 (2µg/ml), AMD-3100 (2µg/ml) (AIDS Research and Reagents Program, NIAID, Bethesda, MD), or RANTES (2µg/ml). We also performed a titration for sCD4 ranging from 0.001 to 10 µg/mL.
Statistics
Experiments were repeated at least four times and p values (P) were calculated using a 
Results
Detection of Annexin V and DR5 in HIV-1-infected patients and controls
We tested 22 HIV-1-infected patients and 16 healthy, uninfected controls for plasma TRAIL levels. HIV-1-infected patients exhibited increased levels of plasma TRAIL compared to uninfected controls (2617±729 vs 730±320 pg/ml (mean±SEM), P=0.0001), confirming our previous finding in a separate cohort of HIV-1-infected patients 24 .
Apoptosis and DR5 expression were measured in CD4 + T cells from patients and controls directly after Ficoll separation and without culture. We also observed an increased percentage of CD4 + T cells that expressed Annexin V (23±8%) and DR5 (16±6%) compared to the levels of Annexin V (11±3%, P=3x10 -5 ) and DR5 expression (7±3%,
P=2x10
-6 ) in healthy controls (Fig. 1A) . respectively, compared to control) ( Fig. 2A) .
We then tested whether isolated CD4 + and CD8 + cells from HIV-1-seronegative donors would also express Annexin V when cultured with infectious HIV-1 for 24 hours. This is insufficient time for productive viral replication in our culture system, suggesting a mechanism that involved virus exposure, but not viral replication. Furthermore, we compared the effects of culturing CD4 + and CD8 + cells with infectious and noninfectious AT-2 HIV-1. Our experiments indicated that infectious HIV-1MN and AT-2 HIV-1MN
were equally effective at inducing Annexin V expression in isolated CD4 + T cells, but neither induced significant apoptosis of CD8 + T cells (Fig. 2B) . These results were similar to those seen for the CD4 + and CD8 + T cell subsets when unfractionated PBMC were cultured with infectious HIV-1 (compare Fig. 2B (Fig. 2 F) . In contrast, culture of CD8 + T cells with AT-2 HIV-1 MN induced less than 1% increase of DR5 expression compared to controls (Fig. 2F) .
Thus, AT-2 HIV-1MN induced expression of the DR5 TRAIL death receptor on CD4 + but not on CD8 + T cells.
Role of type I interferon and DR5 in T cell apoptosis
The above in vitro results suggest that TRAIL/DR5 contributes to apoptosis induced by culturing CD4 + cells with infectious or noninfectious HIV-1. We then tested whether the CD4 + T cell apoptosis could be blocked by monoclonal antibodies to TRAIL or DR5.
TRAIL antibody reduced Annexin V + cells by 50% (P=0.01, compared to isotype control), while anti-DR5 monoclonal antibody inhibited CD4 + T cell Annexin V positivity by 62% (P=0.008, compared to isotype control) (Fig. 3A) . In contrast, a Fas- (Fig. 3B) . After 24 hours, control and AT-2 HIV-1 plus anti-DR5-treated cells were stained using an anti-mouse-PE-labeled antibody, and cells cultured with AT-2 HIV-1 plus isotype were stained using the anti-DR5 antibody, followed by anti-mouse-PE-labeled. Cells were then acquired and analyzed by flow cytometry. The anti-DR5 (Fig. 3A) . Furthermore, anti-IFN-/ completely blocked AT-2 HIV-1MN-induced TRAIL protein (Fig. 3C ) and mRNA expression (Fig. 3D) . Thus, TRAIL expression and apoptosis of CD4 + T cells induced by HIV-1 in our in vitro experiments are type I interferon dependent. We also verified that these CD4 + T cells were activated caspase-3 + , a late marker of apoptosis. We showed that caspase-3 activation in AT-2 HIV-1-exposed CD4 + T cells was blocked by anti-IFN-/ antibodies (Fig. 3E ).
pDCs were recently shown to be potent producers of type I interferon after HIV-1 exposure 38 . Therefore, we tested whether isolated pDCs cells would produce IFN-after exposure to AT-2 HIV-1. We found that the pDCs produced 10-11 ng/mL/10 5 cells after 24-hours exposure to AT-2 HIV-1 MN and AT-2 HIV-1 Ada , (Fig. 3F) . Similar results were obtained using infectious HIV-1 (data not shown). Up to 1% of our CD4 + positively selected cells were pDCs (CD4 + CD123 + BDCA2 + ), which could account for the type I interferon produced.
Effect of HIV-1 entry inhibitors on apoptosis and DR5 expression in CD4 + T cells
We tested whether HIV-1-induced apoptosis and DR5 mRNA expression would be inhibited by sCD4-IgG, that blocks the interaction between viral gp120 and CD4 and by AMD-3100 and RANTES, that block CXCR4 and CCR5 coreceptor binding, respectively. The results (Fig. 4A) (Fig. 4 C) .
Finally, we demonstrated that sCD4-IgG also inhibited DR5 mRNA expression by CD4 + T cells cultured with AT-2 HIV-1 MN or AT-2 HIV-1 Ada (Fig. 4C) . These results are consistent with a triggering mechanism that is dependent on very early CD4/gp120 binding events.
DR5 expression, CD4 count and viral load in a longitudinal study of HAART patients
To assess the potential clinical relevance of our in vitro findings, we compared the changes in DR5 mRNA expression in CD4 + T lymphocytes with CD4 counts and viral loads in eight drug-naïve, HIV-1-infected patients who received HAART during a 40-week longitudinal study. Because only CD4 + T cells, and not CD8 + T cells, expressed DR5, we used CD4 mRNA as an internal standard to normalize DR5 mRNA expression.
Comparisons of the viral loads, CD4 counts and DR5/CD4 mRNA expression are shown
For personal use only. on November 16, 2017. by guest www.bloodjournal.org From for weeks 0 and 40 in Fig. 5A . HAART reduced viral loads and increased CD4 counts in 7/8 patients, indicated as HAART responders. The DR5/CD4 mRNA ratio decreased in 5/7 of these responders, along with HAART-induced viral load reductions, and increased CD4 counts (Fig. 5A) . The data from the patient who appeared to be a HAART nonresponder (patient 4), showed no appreciable decrease in viral load, a decrease in CD4 count, and a slight increase in DR5/CD4 mRNA at 40 weeks. Figure 5B Our finding that sCD4-IgG effectively inhibited AT-2 HIV-1-induced DR5 expression and apoptosis of CD4 + T cell demonstrate that the binding of gp120 to CD4 is essential for inducing TRAIL/DR5 apoptosis. This result also demonstrates that the apoptosis observed was only due to the HIV-1 particles. In contrast, coreceptor inhibitors did not have any effect, suggesting that the binding coreceptor step is not essential for inducing apoptosis. This is in agreement with another report demonstrating that CXCR4-and CCR5-tropic HIV isolated are equally cytopathic to CD4 + T cells in human lymphoid tissue 50 . However we can not exclude the possibility that these two HIV-1 isolates might have used other coreceptors for inducing these effects.
Our analysis of clinical samples showed that the percentage of CD4 + T cells entering apoptosis correlates with expression of the TRAIL death receptor 5 (DR5) in HIV-1-infected patients. In contrast, no correlation was observed in healthy controls. To explore the link between DR5 and CD4 count, we studied samples from patients receiving HAART. We quantified DR5 and CD4 mRNA expression in T lymphocytes before and after HAART. We showed that 6/7 patients who were responsive to HAART by decreasing viral load and increasing CD4 counts, exhibited decreases in DR5/CD4 mRNA ratio. Furthermore, the CD4 count decrease seen in the patient with a viral rebound was associated with an increase in the DR5/CD4 mRNA ratio, which would have been predicted by our model. The inverse association between CD4 count and DR5/CD4 mRNA could be the reflection of two non-mutually exclusive possibilities: 1)
general decrease of DR5 mRNA expression in the existing CD4 + T cells, and/or 2) reduction of the DR5/CD4 mRNA ratio resulting from increased numbers of CD4 + T cells that do not express elevated DR5. In either case, the overall result was a reduction of DR5 mRNA expression by the CD4 + T cell population as the CD4 count increased. This result is consistent with the data of our cross-sectional study of HIV-1-infected patients. For (patients 2 and 3); and the HAART nonresponder (patient 4). The plasma TRAIL levels of patient 1 and 4 were previously shown in our earlier study 24 . The plasma TRAIL levels of patients 2 and 3 are new data.
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